Opdivo

BMS pays $475m for Dragonfly’s IL-12 immunotherapy programme

As well as testing the drug as a mono therapy, Dragonfly is also studying DF6002 in combination with PD-1 inhibiting treatment, such as BMS’ Opdivo (nivolumab).

Bristol-Myers Squibb’s revenues rise on Celgene acquisition

Sales of immunotherapy Opdivo decreased due to COVID-19 impact. Bristol-Myers Squibb has posted better-than-expected results in the second quarter of the year, with shares in the company ... One concerning caveat among the otherwise positive results was

Roche’s Tecentriq combo scores FDA approval for melanoma

However, Roche is likely to face fierce competition from rival checkpoint inhibitors, namely Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo which have already been on the market ... Opdivo, on the other hand, was first

NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer

number of cancer immunotherapies including Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab).

BMS suspends new clinical trials as COVID-19 cases rise in US

Both of those are also under review in Europe. Following after is an FDA review of checkpoint inhibitor combination Opdivo (nivolumab) and Yervoy (ipilimumab) in first-line non-small cell lung

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]